Literature DB >> 19176215

Retinal vascular repair and neovascularization are not dependent on CX3CR1 signaling in a model of ischemic retinopathy.

Lian Zhao1, Wenxin Ma, Robert N Fariss, Wai T Wong.   

Abstract

Proliferative retinal neovascularization occurring in response to ischemia is a common mechanism underlying many retinal diseases. In recent studies, retinal microglia have been shown to influence pathological neovascularization, likely through an exchange of cellular signals with associated vascular elements. CX3CR1 is a chemokine receptor located specifically on microglia; its ligand, CX3CL1 (also known as fractalkine or neurotactin) displays pro-angiogenic activity both in in vivo and in vitro. Discovering the regulatory role, if any, that CX3CR1 signaling may have in ischemic retinopathy will shed light on the molecular nature of microglial-vascular interactions and clarify potential targets for future therapy. In this study, we examined this question by inducing and comparing ischemic vascular changes in transgenic mice in which CX3CR1 signaling is either preserved or ablated. Using a well-known oxygen-induced retinopathy (OIR) model, we induced ischemic retinopathy in transgenic mice in which the gene for CX3CR1 has been replaced by green fluorescent protein (GFP) and their wild type controls. CX3CR1(+/+), CX3CR1(+/GFP), and CX3CR1(GFP/GFP) transgenic mice were exposed to 75% oxygen for 5 days starting from postnatal day (P) 7, and then transferred back to room air. At P12 and P17, the extents of vascular repair and neovascularization, and associated changes in retinal microglia distribution, were quantified and compared between mice of different genotypes. Neuronal loss in the retina following ischemia was also evaluated in paraffin sections. Our results show that: (1) CX3CR1 signaling is not required for normal vascular, microglial, and neuronal development in the retina in the first postnatal week, (2) the processes of retinal vascular repair and neovascularization following ischemia occur similarly with and without CX3CR1 signaling, (3) microglia redistribution in the retina and their association with vascular elements occurring concurrently is independent of CX3CR1, and (4) CX3CR1 does not influence the extent of neuronal cell loss in the retina following ischemia. Taken together, our findings indicate that the regulatory signals exchanged between microglia and vascular elements in the ischemic retinopathy animal model are unlikely to involve CX3CR1. These results have implications on therapeutic approaches to, pathological neovascularization involving the modulation of chemokine signaling in general, and the regulation of CX3CR1 signaling specifically.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19176215      PMCID: PMC2683176          DOI: 10.1016/j.exer.2008.12.013

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  35 in total

1.  T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification.

Authors:  Eyal Banin; Michael I Dorrell; Edith Aguilar; Matthew R Ritter; Christopher M Aderman; Alexandra C H Smith; Jeffrey Friedlander; Martin Friedlander
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

Review 2.  The many roles of chemokines and chemokine receptors in inflammation.

Authors:  Israel F Charo; Richard M Ransohoff
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

3.  Characterization of vascular development in the mouse retina.

Authors:  S E Connolly; T A Hores; L E Smith; P A D'Amore
Journal:  Microvasc Res       Date:  1988-11       Impact factor: 3.514

4.  Microglia and macrophages are increased in response to ischemia-induced retinopathy in the mouse retina.

Authors:  Michael H Davies; Joshua P Eubanks; Michael R Powers
Journal:  Mol Vis       Date:  2006-05-10       Impact factor: 2.367

Review 5.  Angiogenesis and plasticity: role of erythropoietin in vascular systems.

Authors:  Zhao Zhong Chong; Jing-Qiong Kang; Kenneth Maiese
Journal:  J Hematother Stem Cell Res       Date:  2002-12

6.  Expression of CX3C chemokine, fractalkine, and its receptor CX3CR1 in experimental autoimmune anterior uveitis.

Authors:  I-Mo Fang; Chang-Pin Lin; Chung-May Yang; Muh-Shy Chen; Chang-Hao Yang
Journal:  Mol Vis       Date:  2005-07-01       Impact factor: 2.367

7.  Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization.

Authors:  Diego G Espinosa-Heidmann; Ivan J Suner; Eleut P Hernandez; Dagoberto Monroy; Karl G Csaky; Scott W Cousins
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-08       Impact factor: 4.799

Review 8.  Macrophages and angiogenesis.

Authors:  C Sunderkötter; K Steinbrink; M Goebeler; R Bhardwaj; C Sorg
Journal:  J Leukoc Biol       Date:  1994-03       Impact factor: 4.962

9.  Oxygen-induced retinopathy in the mouse.

Authors:  L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-01       Impact factor: 4.799

10.  Constitutive and inflammatory mediator-regulated fractalkine expression in human ocular tissues and cultured cells.

Authors:  Matthew D Silverman; David O Zamora; Yuzhen Pan; Paul V Texeira; Seung-Hee Baek; Stephen R Planck; James T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-04       Impact factor: 4.799

View more
  17 in total

1.  Ferrochelatase regulates retinal neovascularization.

Authors:  Sardar Pasha Sheik Pran Babu; Darcy White; Timothy W Corson
Journal:  FASEB J       Date:  2020-07-27       Impact factor: 5.191

Review 2.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

3.  Diabetes mellitus: channeling care through cellular discovery.

Authors:  Kenneth Maiese; Yan Chen Shang; Zhao Zhong Chong; Jinling Hou
Journal:  Curr Neurovasc Res       Date:  2010-02       Impact factor: 1.990

4.  Naloxone ameliorates retinal lesions in Ccl2/Cx3cr1 double-deficient mice via modulation of microglia.

Authors:  Defen Shen; Xiaoguang Cao; Lian Zhao; Jingsheng Tuo; Wai T Wong; Chi-Chao Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-02       Impact factor: 4.799

Review 5.  The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy.

Authors:  Erica L Fletcher; Laura E Downie; Kate Hatzopoulos; Kirstan A Vessey; Michelle M Ward; Chee L Chow; Michael J Pianta; Algis J Vingrys; Michael Kalloniatis; Jennifer L Wilkinson-Berka
Journal:  Doc Ophthalmol       Date:  2009-09-08       Impact factor: 2.379

6.  FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis.

Authors:  Yan Chen Shang; Zhao Zhong Chong; Jinling Hou; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2009-11       Impact factor: 1.990

7.  Anti-angiogenic and anti-inflammatory effect of Magnolol in the oxygen-induced retinopathy model.

Authors:  Boyu Yang; Yue Xu; Shanshan Yu; Yongsheng Huang; Lin Lu; Xiaoling Liang
Journal:  Inflamm Res       Date:  2015-11-07       Impact factor: 4.575

8.  Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy.

Authors:  Franziska Fischer; Gottfried Martin; Hansjürgen T Agostini
Journal:  J Neuroinflammation       Date:  2011-09-23       Impact factor: 8.322

Review 9.  The vitamin nicotinamide: translating nutrition into clinical care.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Molecules       Date:  2009-09-09       Impact factor: 4.411

10.  The effects of CX3CR1 deficiency and irradiation on the homing of monocyte-derived cell populations in the mouse eye.

Authors:  Jelena M Kezic; Paul G McMenamin
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.